Summary
A feasibility study is requested to assess Minnesota's current capacity for rare-disease cell and gene therapy across research, innovation, commercialization, biomanufacturing, and delivery, and to provide a strategic gap analysis with recommendations for national leadership positioning. The solicitation appears linked to state legislative direction for the commissioner of health to conduct a comprehensive study on cell and gene therapies for rare diseases and to submit a report (statute directs MDH to produce findings and recommendations by January 1, 2028). The BidNet listing shows the solicitation published 2026-06-26 and closing 2026-07-24, and the original buyer-hosted procurement page or a solicitation PDF was not found in the reviewed corpus.